Introduction
The PI3K signal transduction pathway plays an important role in cancer development (Cantley and Neel, 1999; Mills et al., 2001) . For example, the PTEN tumor suppressor protein may be functionally deleted in tumors nearly as frequently as p53. The PTEN phosphatase negatively regulates the growth-and survival-promoting PI3K signaling pathway by dephosphorylating phosphoinositol phosphates at the 3 0 position. PTEN null mice are not viable, but it has been shown that haplosufficiency for PTEN promotes tumor formation (Di Cristofano et al., 1998; Suzuki et al., 1998; Podsypanina et al., 1999; Kwabi-Addo et al., 2001) . Intriguingly, tumor formation resulting from PTEN ablation is suppressed by treatment of the mice with the rapamycin derivative CCI-779, a specific inhibitor of the mTOR kinase Podsypanina et al., 2001) . mTOR is the mammalian homolog of the yeast TOR1 and TOR2 proteins that play a central role in coupling yeast cell growth to extracellular nutrient levels by regulating protein turnover, translation, and transcription (Schmelzle and Hall, 2000) . The ability of rapamycin to suppress tumor formation in PTEN þ /À mice has been attributed to the mTOR dependence of PI3K signaling.
Several studies have demonstrated an increase in mTOR kinase activity upon expression of an activated form of Akt, which lies downstream of PI3K (Scott et al., 1998; Nave et al., 1999; Sekulic et al., 2000) . Consistent with these results, when mammalian cells are withdrawn from growth factor, the two most well-studied mTOR target proteins, 4EBP1 and p70S6K, are dephosphorylated to a similar degree as in rapamycin-treated cells while expression of activated Akt can maintain their phosphorylation (Sonenberg and Gingras, 1998) . Several possible mechanisms for Akt-dependent activation of mTOR have been suggested. The recent discovery that the tuberous sclerosis complex (TSC) regulates the phosphorylation of 4EBP1 and p70S6K on mTOR-dependent sites has led to a model in which growth factors regulate mTOR activity through Akt and TSC1/2. Akt phosphorylates TSC2 resulting in its inactivation and degradation releasing mTOR from TSC-mediated inhibition ( (Inoki et al., 2002; Potter et al., 2002; reviewed in McManus and Alessi, 2002) . In addition, recent studies have shown that TSC2 is a GAP for Rheb, a growth-promoting GTPase, and suggest that the effects of Rheb on cell growth are mediated by TOR (Garami et al., 2003; Saucedo et al., 2003; Stocker et al., 2003; Tee et al., 2003; Zhang et al., 2003; Inoki et al., 2003a) . Intracellular nutrient levels also may affect mTOR activity through the TSC/Rheb pathways (Gao et al., 2002; Garami et al., 2003; Saucedo et al., 2003; Stocker et al., 2003; Tee et al., 2003; Zhang et al., 2003; Inoki et al., 2003a, b) .
It has also been suggested that Akt directly regulates mTOR kinase activity via phosphorylation (Scott et al., 1998; Nave et al., 1999; Sekulic et al., 2000) . mTOR contains two Akt consensus phosphorylation sites that are phosphorylated in response to growth factors and the expression of activated forms of Akt. Phosphorylation of mTOR at these sites correlates with increased mTOR kinase activity both in cells and in vitro. Intriguingly, an mTOR antibody whose binding site overlaps these Akt consensus phosphorylation sites stimulates mTOR kinase activity in vitro (Brunn et al., 1997) . Based on these results, the region of mTOR containing the Akt phosphorylation sites and the antibody-binding site, amino acids 2430-2450, was proposed as a repressor domain (Sekulic et al., 2000) . Consistent with this hypothesis, DTOR, a mutant lacking the putative repressor domain, displays enhanced insulin-independent activity (Sekulic et al., 2000) .
As mTOR activity appears to be modulated either directly or indirectly by growth factor signaling, it was possible that mTOR activation might be sufficient to block growth factor withdrawal-induced apoptosis. To test this hypothesis, we evaluated whether the expression of wild-type mTOR or the activated DTOR mutant could protect cells from growth factor deprivation. Growth factor withdrawal results in the degradation of nutrient transporters, a reduction in the rate of glycolysis, a decline in the mitochondrial membrane potential, and cellular atrophy. These changes precede the changes in mitochondrial physiology that culminate in cytochrome c release and caspase activation. Expression of the DTOR mutant, but not wild-type mTOR, prevented the development of these preapoptotic changes in cellular metabolism upon growth factor deprivation. While the induction of Bim L and the loss of Bcl-X L proteins following growth factor withdrawal were unaffected by DTOR expression, the conformational changes in the proapoptotic protein Bax that result in its activation and insertion into the mitochondrial outer membrane were forestalled by DTOR but not mTOR expression. Furthermore, the expression of DTOR but not wild-type mTOR conferred long-term, growth factor-independent cell survival and promoted colony formation in soft agar by p53 null mouse embryonic fibroblasts. These results suggest that the loss of mTOR signaling contributes to growth factor withdrawal-induced apoptosis and that mTOR may possess transforming potential by promoting cell autonomous survival.
Results
DTOR partially maintains the phosphorylation of 4EBP1 in the absence of growth factor mTOR contains two Akt consensus phosphorylation sites (Thr2446 and Ser2448) that are phosphorylated in response to insulin, serum, and myrAkt expression (Scott et al., 1998; Nave et al., 1999; Sekulic et al., 2000) .
Phosphorylation at these sites has been reported to increase mTOR kinase activity in cells and in vitro. Consistent with the designation of this region (aa 2430-2450) as a repressor domain, the in vitro kinase activity of mTOR increases 3.5-to 10-fold when this domain is deleted (Sekulic et al., 2000) . We wished to determine whether DTOR was capable of supporting other mTORdependent activities in the absence of growth factor signaling. To this end, we expressed AU-1-tagged wildtype mTOR and DTOR in the IL-3-dependent murine hematopoetic cell line FL5.12 (Figure 1a ). FL5.12 cells were selected for these studies as they are completely dependent on a single factor, IL-3, for cell growth, proliferation, and survival and thus well suited for studies of growth factor signaling.
To confirm that DTOR possessed growth factorindependent activity in FL5.12 cells, we evaluated the levels of 4EBP1 phosphorylation in FL5.12 cells expressing empty vector, mTOR, or DTOR in the (Figure 1b ). 4EBP1 is phosphorylated at multiple sites and thus runs as a series of three bands in SDS-PAGE with the most phosphorylated species possessing the lowest electrophoretic mobility. Upon IL-3 withdrawal, 4EBP1 was rapidly dephosphorylated as expected. Forced expression of wild-type mTOR had no effect on IL-3 withdrawalinduced 4EBP1 dephosphorylation. In contrast, DTOR expression partially maintained 4EBP1 phosphorylation despite the loss of growth factor signaling. Low levels of 4EBP1 phosphorylation were maintained as long as 48 h after IL-3 withdrawal in DTOR-expressing cells (Figure 1c) . These results support the conclusions drawn in other cell lines that DTOR possesses increased growth factor-independent activity relative to wild-type mTOR.
DTOR supports growth factor-independent amino-acid transporter expression
Previous work has suggested that the downregulation and lysosomal trafficking of 4F2hc upon growth factor withdrawal is an mTOR-dependent process (Edinger and Thompson, 2002) . 4F2hc is an amino-acid transporter-associated protein that has been shown to be upregulated upon lymphocyte activation and in transformed cells (Palacin et al., 1998; Deves and Boyd, 2000) . We wished to determine whether DTOR expression could support 4F2hc surface expression in the absence of IL-3. To perform these studies, the antiapoptotic protein Bcl-X L was expressed in addition to mTOR or DTOR. Bcl-X L expression prevents cell death but does not interfere with the downregulation of 4F2hc or other nutrient transporters from the cell surface, permitting the comparison of the effects of mTOR and DTOR expression on 4F2hc trafficking in the absence of the confounding effects of cell death. When IL-3 was withdrawn from control cells, 4F2hc surface staining declined and a focal, intracellular staining pattern developed ( Figure 2 ). These brightly staining intracellular dots co-stain with lysosomal markers (data not shown). While expression of wild-type mTOR had no effect on 4F2hc downregulation and trafficking, cells expressing DTOR were rendered IL-3 independent for 4F2hc expression as no change in 4F2hc localization was observed after 24 h of growth factor withdrawal.
Expression of DTOR partially supports glycolysis following growth factor deprivation
The rate of glycolysis declines rapidly upon growth factor withdrawal (Vander Heiden et al., 2001) . Expression of activated forms of Akt largely prevents this decrease in glycolytic rate . However, rapamycin treatment compromises the ability of Akt to support growth factor-independent glycolysis (unpublished data). In addition, rapamycin treatment has been shown to decrease the levels of mRNA transcripts for glycolytic enzymes both in yeast and mammalian cells (Hardwick et al., 1999; Peng et al., 2002) . These results suggest that loss of mTOR activity may contribute to the decrease in the glycolytic rate following growth factor withdrawal. Thus, we evaluated whether mTOR or DTOR expression could support glycolysis in the absence of trophic support ( Figure 3 ). Following 6 h of IL-3 withdrawal, the glycolytic rate decreased to a basal level. The expression of wild-type mTOR did not affect this decline. In cells expressing DTOR, however, the glycolytic rate was found to be maintained at a level fivefold higher than that observed in control cells. Thus, DTOR but not mTOR expression promoted growth factor-independent glucose metabolism.
Growth factor withdrawal-induced cellular atrophy is blunted by DTOR expression
Studies involving the specific mTOR inhibitor rapamycin and mTOR RNAi have suggested that mTOR contributes to the regulation of mammalian cell size (Fingar et al., 2002; Kim et al., 2002) . We therefore Figure 2 Effect of mTOR or DTOR expression on growth factor withdrawal-induced downregulation of amino-acid transporters. Control FL5.12 cells expressing Bcl-X L or cells also expressing wild-type mTOR or DTOR were withdrawn from IL-3 for 24 h, fixed, and examined by immunofluorescence for 4F2hc localization. Scale bar is 10 mm Figure 3 DTOR supports growth factor-independent glycolysis. FL5.12 cells expressing empty vector, wild-type mTOR, or DTOR were incubated in the presence or absence of IL-3 for 6 h and glycolytic rate evaluated as described in Materials and methods. Error bars represent s.e.m. A representative experiment of three similar experiments is shown determined whether the expression of DTOR affected cell size regulation. FL5.12 cells expressing empty vector, wild-type mTOR, or DTOR were grown in IL-3 or withdrawn from growth factor for 14 h and cell size evaluated by flow cytometry (Figure 4 ). Cells expressing Bcl-X L or myrAkt were included as controls. Analysis was restricted to propidium iodide-negative cells with a 2N DNA content to eliminate the confounding effects of cell death and cell cycle position on cell size. Following growth factor deprivation, atrophy was observed in all cell lines. However, cells expressing DTOR maintained a larger cell size than vector control cells. In fact, the effects of DTOR on cell size were of the same magnitude as those produced by myrAkt. The expression of wildtype mTOR or Bcl-X L had no effect on cell size in the presence of IL-3 or following IL-3 withdrawal.
DTOR expression supports mitochondrial homeostasis despite growth factor withdrawal
The mitochondrial membrane potential (DCm) declines following growth factor withdrawal (Vander Heiden et al., 1997) . One possible explanation for this decrease is that mitochondria become substrate limited due to decreases in the rates of nutrient uptake and glycolysis. As DTOR partially supported both 4F2hc expression and glycolysis and reduced the amount of catabolic cellular atrophy upon growth factor withdrawal, it was possible that mitochondrial bioenergetics were better maintained in these cells. To test this hypothesis, we determined the mitochondrial membrane potential in cells expressing empty vector, wild-type mTOR, or DTOR both in the presence and absence of IL-3 ( Figure 5 ). Following 14 h of growth factor withdrawal, DCm declined in control cells as expected. Expression of wild-type mTOR had no effect on the decrease in DCm following IL-3 withdrawal. Cells expressing DTOR, in contrast, showed almost no change in the mitochondrial membrane potential despite growth factor deprivation.
It has been suggested that changes in cellular bioenergetics following growth factor withdrawal disrupt mitochondrial physiology triggering the insertion of proapoptotic Bcl-2 family members into the mitochondrial outer membrane and the release of proapoptotic mediators. The conformational changes that precede the membrane insertion of one of these proteins, Bax, can be monitored through the use of conformationally sensitive antibodies such as 6A7 (Gross et al., 1998; Nechushtan et al., 1999) . This monoclonal antibody recognizes an epitope in Bax that is not exposed until cells are triggered to undergo apoptosis. As DTOR was able to maintain mitochondrial homeostasis ( Figure 5 ), we wished to determine whether DTOR also Loss of mTOR activity contributes to the reduction in Dcm following growth factor withdrawal. FL5.12 cells expressing empty vector, wild-type mTOR, or DTOR were withdrawn from IL-3 for 14 h and the mitochondrial membrane potential evaluated using TMRE and flow cytometry. Analysis was restricted to live cells. Complete dissipation of the mitochondrial proton gradient was achieved by the addition of CCCP and chloroquine (CQ). One representative experiment of three is shown inhibited the mitochondrial insertion of the proapoptotic protein Bax. Cells expressing empty vector, wild-type mTOR, or DTOR were maintained in the presence or absence of IL-3 for 14 h and the conformational state of Bax probed by intracellular staining with the 6A7 antibody and flow cytometry (Figure 6a ). Cells with a sub-G1 DNA content were excluded from the analysis to avoid staining artifacts. When cells were maintained in IL-3, 6A7 staining was detected in less than 1% of cells similar to results obtained with an isotype-matched control antibody. When control cells were withdrawn from growth factor for 14 h, 41% of the cells exhibited intracellular staining with the conformationally sensitive Bax antibody. Expression of wild-type mTOR had no effect on growth factor withdrawal-induced conformational changes in Bax. In contrast, cells expressing DTOR exhibited markedly decreased 6A7 positivity following IL-3 withdrawal.
Another proapoptotic Bcl-2 family member, Bim, also plays a role in growth factor withdrawal-induced death (Bouillet et al., 1999; Dijkers et al., 2000; Shinjyo et al., 2001; Dijkers et al., 2002) . Thus, we next evaluated whether the expression of DTOR blocked the increase in Bim L protein levels normally seen following growth factor deprivation as a part of its antiapoptotic mechanism. Vector control or DTOR-expressing cells were maintained in the presence or absence of IL-3 for 14 h and the levels of Bim L protein evaluated by Western blot (Figure 6b ). An increase in Bim L protein level was detected following IL-3 withdrawal. However, the induction of Bim L was unaffected by expression of the activated mTOR mutant, DTOR. As the levels of Bcl-X L protein have been reported to decline following growth factor deprivation, these lysates were also probed for Bcl-X L . As expected, Bcl-X L protein levels declined following IL-3 withdrawal. This decline was not altered in DTOR-expressing cells. Thus, DTOR does not maintain mitochondrial homeostasis by preventing the induction of Bim L protein or the decline in Bcl-X L protein levels that normally accompanies growth factor withdrawal.
DTOR promotes growth factor-independent, nutrientdependent cell survival
We next determined whether the ability of DTOR to maintain DCm ( Figure 5 ) and inhibit Bax conformational change (Figure 6a ) translated into protection from growth factor withdrawal-induced apoptosis. Cells expressing empty vector, wild-type mTOR, or DTOR were withdrawn from IL-3 and cellular viability measured at the indicated time points by propidium iodide exclusion (Figure 7a ). Cells expressing myrAkt or Bcl-X L were included as controls. Vector control cells died with the expected kinetics following IL-3 withdrawal. In contrast, cells expressing DTOR exhibited long-term growth factor-independent cell survival similar to that achievable through myrAkt expression. DTOR-expressing cells could be rescued by IL-3 readdition after 4 days of growth factor withdrawal, a time point at which vector control cells were not recoverable (Figure 7b ). Although the survival curve of cells expressing wild-type mTOR is superimposable with that of vector control cells (Figure 7a) , re-addition of IL-3 after 4 days of IL-3 withdrawal resulted in delayed recovery of live cells from mTOR-expressing cell lines (Figure 7b ).
To confirm that the increased growth factor-independent cell survival observed in the DTOR-expressing lines was a direct result of transgene expression, the effect of rapamycin on DTOR-mediated cell survival was evaluated ( Figure 7c ). While rapamycin had no effect on the survival of vector control cells, DTOR was no longer able to protect cells from growth factor withdrawalinduced apoptosis in the presence of 20 nM rapamycin.
Our data are consistent with a model in which DTOR promotes growth factor-independent cell survival by maintaining nutrient uptake and cellular bioenergetics despite growth factor deprivation. If this model for DTOR-dependent survival is correct, DTOR should not protect cells from apoptosis induced by nutrient deprivation. We therefore tested the ability of DTOR and mTOR to inhibit apoptosis triggered by amino-acid or glucose withdrawal (Figure 7d ). Withdrawal of these nutrients produces cell death with similar kinetics to that obtained following IL-3 deprivation. Following the Figure 6 Effect of DTOR expression on Bcl-2 family members. (a) FL5.12 cells expressing empty vector, wild-type mTOR, or DTOR were withdrawn from IL-3 for 14 h, fixed, and the conformational status of Bax determined by staining with the antibody 6A7 followed by flow cytometry. Numbers represent the percent of cells positive for 6A7. Cells with less than a 2N DNA content were excluded from the analysis. One of three similar experiments is presented. (b) Vector control or DTOR-expressing cells were withdrawn from IL-3 for 14 h and lysates probed for Bim L , Bcl-X L , or actin protein levels by Western blotting. A 50 mg portion of total protein was loaded per lane withdrawal of amino acids or glucose, vector control cells displayed a dramatic loss of cell viability. As predicted, neither mTOR nor DTOR expression protected cells from apoptosis under either of these conditions. In contrast, Bcl-X L mediated protection from nutrient withdrawal as expected based on previous studies and data not shown).
Increased mTOR activity promotes cellular transformation
Neoplastic transformation is suppressed in part by a cell intrinsic default apoptotic pathway that is repressed by extracellular growth factors. Because DTOR was able to promote growth factor-independent cell survival in FL5.12 cells, we wished to determine whether DTOR also had activity in cellular transformation assays. To this end, low-passage p53À/À MEFs were transfected with constructs directing the expression of mTOR or DTOR linked to GFP by means of an IRES sequence. A population of cells stably expressing either mTOR or DTOR was isolated by flow cytometric sorting for cells expressing high levels of GFP. Relative levels of mTOR expression were determined by Western blotting for total and epitope-tagged mTOR/DTOR (Figure 8) .
To assess the transforming potential of mTOR and DTOR, these cells were evaluated in a colony forming assay in soft agar (Figure 8 ). Colony formation in soft agar has been well established to correlate closely with the ability to form tumors in vivo (Freedman and Shin, 1974; Li et al., 1989) . p53À/À MEFs expressing GFP alone formed a low number of colonies in soft agar. Although these cells lack the p53 protein, the Rb pathway is intact in these cells and may suppress transformation. We therefore inactivated Rb by expressing the adenoviral E1A protein by retroviral transduction. As previously reported (Degenhardt et al., 2002) , ablation of p53 and Rb functions alone is inadequate to transform fully primary MEFs. Consistent with the growth factor-independent survival advantage conferred by wild-type mTOR expression, the expression of wildtype mTOR increased the number of colonies formed both in the presence and absence of E1A two-to threefold. The expression of DTOR, in contrast, resulted in a 10-fold increase in colony formation both in the presence and absence of E1A.
Discussion
Although numerous studies using the mTOR inhibitor rapamycin have suggested that mTOR signaling is required for specific antiapoptotic pathways, the DTOR mutant provides the first indication that the activation Figure 8 mTOR activity promotes cellular transformation. p53À/ À MEFs expressing empty vector, wild-type mTOR, or DTOR were generated as described in the text and probed for transgene expression by Western blotting (inset) with the AU-1 antibody or for total mTOR expression. These cells were either left uninfected or transduced with retrovirus encoding E1A as indicated, plated in soft agar, and colony formation evaluated. Error bars represent s.e.m. One of two similar experiments is shown of mTOR is sufficient to inhibit growth factor withdrawal-induced apoptosis. Expression of the activated mTOR construct, DTOR, abrogated or delayed the growth factor withdrawal-induced changes in 4EBP1 phosphorylation, 4F2hc degradation, glycolytic rate, cell size, mitochondrial membrane potential, and Bax activation. The expression of wild-type mTOR, in contrast, did not affect these parameters. In addition to preventing the development of a preapoptotic cellular phenotype, DTOR promoted growth factor-independent cell survival while mTOR expression conferred little to no survival advantage. Based on the observation that DTOR, but not mTOR, promotes a nutrient-replete phenotype while protecting cells from apoptosis, it appears that growth factors signal to and activate mTOR to support the uptake of extracellular nutrients and maintain cellular bioenergetics and that mTOR activity is not regulated solely by intracellular nutrient or ATP levels.
The TOR protein is highly conserved from yeast to mammals. In yeast, TOR regulates diverse cellular processes involved in growth control in a nutrientresponsive manner (Schmelzle and Hall, 2000) . When amino-acid levels are low, yeast TOR activity is suppressed through an incompletely understood mechanism. This dependence of TOR activity on extracellular nutrient levels provides a mechanism for coupling yeast cell growth to the available nutrient pool and facilitates cell survival in nutrient-poor environments. In contrast to unicellular organisms, mammalian cells in situ are constantly supplied with extracellular nutrients at levels maintained within a narrow range through homeostatic mechanisms functioning on the organismal level. Thus, cellular growth in a multicellular organism is not, in general, limited by substrate availability. Rather, extrinsic growth factors regulate the ability of mammalian cells to access extracellular nutrients by controlling the cell-surface expression of nutrient transporters (Edinger and Thompson, 2002) . Mammalian TOR is responsive to amino-acid levels, and it has been proposed that mTOR acts as a sensor of the energy charge of the cell (Raught et al., 2001; Inoki et al., 2003b) . Thus, the observed growth factordependent changes in mTOR activity may be in part an indirect response to alterations in the nutrient status and bioenergetic state of the cell produced by growth factor signaling.
The hypothesis that, in addition to nutrient status, growth factor signaling directly modulates mTOR activity is a subject of much interest and debate (Schmelzle and Hall, 2000; Abraham, 2002) . Recent reports indicate that growth factors stimulate mTOR kinase activity by removing TSC-mediated inhibition (reviewed in Manning and Cantley, 2003) . However, it has been suggested by several groups that, in addition to relieving TSC-mediated inhibition, Akt also directly activates mTOR by phosphorylating the repressor domain (Scott et al., 1998; Nave et al., 1999; Sekulic et al., 2000) . We show here that an activated mTOR mutant lacking this repressor domain, DTOR, maintains nutrient transporter expression, glycolytic rate, mitochondrial membrane potential, and cell size despite growth factor withdrawal. These results suggest that mTOR serves not only as a sensor of cellular energy charge as in yeast, but also regulates intracellular nutrient levels and metabolism in response to direct afferent input from growth factor receptors. If the DTOR mutant were simply unable to sense the alterations in cellular nutrient status and metabolism produced by growth factor deprivation and continued to drive translation and growth in the absence of sufficient energy and substrates, then the mitochondrial membrane potential should decline further upon growth factor deprivation rather than being preserved and no survival advantage should be conferred by DTOR expression. Intriguingly, the repressor domain sequence containing the Akt phosphorylation sites that is deleted from DTOR is absent from the homologous yeast TOR1 and TOR2 proteins. Thus, evolutionary pressures may have generated a mammalian TOR protein responsive to regulatory afferent input from extrinsic factors not present in yeast.
Akt-mediated growth factor-independent cell survival has been suggested to depend on the ability of Akt to prevent FOXO3a (FKHR-L1) activation following growth factor withdrawal ( Figure 9 ). The proapoptotic Bcl-2 family member Bim and Fas ligand are both transcriptional targets of FOXO3a, and the induction of these proteins has been shown to play a role in apoptosis (Bouillet et al., 1999; Brunet et al., 1999; Dijkers et al., Figure 9 Akt promotes cell survival through at least two distinct mechanisms. Akt prevents apoptosis in part by inhibiting the transcription of Fas ligand and Bim through the inhibition of FOXO3a. Akt activation also stimulates mTOR kinase activity. The observations that Akt-dependent, growth factor-independent cell survival is blocked by rapamycin treatment and that the activated mTOR mutant DTOR promotes growth factor-independent cell survival suggest that mTOR activation also contributes to Akt-mediated survival. As DTOR does not interfere with Bim induction, the Akt to mTOR pathway appears to be distinct from that by which Akt inactivates FOXO3a 2000; Shinjyo et al., 2001; Dijkers et al., 2002) . Our finding that DTOR inhibits growth factor withdrawalinduced apoptosis but does not prevent Bim induction suggests that mTOR activation represents a FOXO3a-independent survival pathway that is activated by Akt (Figure 9 ). This model is consistent with the observation that Akt stimulation of nutrient uptake, and mitochondrial metabolism require mTOR activity (Edinger and Thompson, 2002) and with the finding that DTOR is not as potent a survival gene as myrAkt, which affects both the mTOR and FOXO3a pathways (Figure 7a ; Bouillet et al., 1999; Brunet et al., 1999; Dijkers et al., 2000; Gottlob et al., 2001; Plas et al., 2001; Shinjyo et al., 2001; Dijkers et al., 2002) .
Growth factor-independent activation of the PI3K pathway has been identified as an important step in oncogenic progression (Cantley and Neel, 1999; Mills et al., 2001; Vogt, 2001) . Expression of constitutively active forms of PI3K or Akt or ablation of the PTEN phosphatase has been shown to promote cellular transformation in multiple systems. Rapamycin has been shown both to limit the survival and growth functions of Akt and to possess activity against PTENdeleted tumors, suggesting that mTOR is a critical downstream mediator of the oncogenic activity of this and other signaling pathways (Kinoshita et al., 1997; Hosoi et al., 1999; Hidalgo and Rowinsky, 2000; Aoki et al., 2001; Neshat et al., 2001; Podsypanina et al., 2001) . While a role in transformation has been suggested for eIF4E (Lazaris-Karatzas et al., 1990) , a molecule whose function is regulated by mTOR, no studies thus far have directly linked mTOR activation to transformation. The observation that DTOR promotes growth factor-independent cell survival and increases the efficiency of colony formation in soft agar suggests that mTOR may in fact be a proto-oncogene.
Materials and methods

Materials and constructs
Antibodies were purchased from the following companies: mTOR, phospho-4EBP1 Thr 37/46, 4EBP1, and anti-rabbit HRP, Cell Signaling Technologies; 4F2hc, anti-Bim, anti-Bax clone 6A7, and mouse IgG1 isotype control, BD Pharmingen; AU-1, Babco. The rabbit polyclonal antiserum to Bcl-X L (13.6) was produced in this laboratory. Propidium iodide, Hoechst 33342, TMRE, and Alexa594 anti-rat secondary were obtained from Molecular Probes. The bicinchoninic acid protein assay kit (Pierce) was used to determine total protein in cell lysates. Wild-type rat mTOR and the DTOR mutant were generously provided by Dr Bob Abraham (Burnham Institute) and cloned into the EF6 mammalian expression vector (Invitrogen) for expression in FL5.12 cells and into an MLV-based retroviral vector (IRES-GFP) for expression in MEFs.
Cell culture
FL5.12 cells were maintained in RPMI (Gibco) supplemented with 10% FCS (Gemini), 8% WEHI conditioned medium, 10 mM HEPES, 55 mM b-mercaptoethanol, antibiotics, and Lglutamine. Stable cell lines were prepared by electroporation followed by drug selection. Following cloning by limiting dilution, stable lines were screened by Western blot for transgene expression level. All experiments were performed in medium containing 500 pg/ml recombinant mouse IL-3 (BD Pharmingen). Glucose-deficient and amino-acid-free RPMI was prepared from chemical components and supplemented with vitamins (Gibco). For nutrient deprivation experiments, complete, glucose-or amino-acid-free medium was prepared with dialysed FCS (Gibco).
Western blotting
Cells were washed with PBS and lysed in RIPA containing protease (Complete, Roche) and phosphatase (Phosphatase Inhibitor Cocktail Set 1, Calbiochem) inhibitors. Lysates were cleared by centrifugation and equal amounts of total cell protein were loaded onto Tris-glycine SDS-PAGE gels (Invitrogen). Proteins were transferred to nitrocellulose, membranes blocked with BLOTTO (5% nonfat dry milk and 0.1% Tween-20 in PBS), and incubated with the indicated antibodies prior to probing with ECL (Amersham Pharmacia).
Fluorescence microscopy
For staining for 4F2hc, FL5.12 cells were fixed for 10 min at RT in 1% paraformaldehyde in PBS, washed in PBS containing 2% FCS and 0.03% saponin in PBS, and then incubated sequentially with primary and secondary antibodies for 1 h at RT in wash buffer containing 0.3% saponin and 10% FCS. Cells were examined using a Nikon E800 fluorescence microscope equipped with a CCD camera. Images were analysed using the Metamorph software package.
Measurement of glycolytic rate
One million FL5.12 cells were resuspended in 0.5 ml of RPMI 1640 medium that had been pre-equilibrated in a 371C incubator under 5% CO 2 . A measure of 10 mCi of 5-[ 3 H]glucose was added to each well and samples incubated for 1 h at 371C in a humidified incubator under 5% CO 2 . Reactions were terminated with 0.5 ml of 0.2 N HCl, and 100 ml of the cell/HCl mixture added to open PCR tubes, which were then placed upright in 4 ml scintillation vials containing 0.5 ml H 2 O. The vials were capped, sealed with parafilm, and incubated for 2 days at RT. During the incubation, 3 H 2 O generated by glycolysis diffused from the PCR tube to the H 2 O in the scintillation vial through evaporation and condensation. The contents of the PCR tube were transferred to a new scintillation vial with 0.5 ml H 2 O, the PCR tube discarded, and scintillation fluid added to both the original (diffused counts) and second (undiffused counts) vials. Vials were evaluated for tritium content using a Wallac Microbeta 1450. The fraction of 3 H 2 O that diffused in 2 days was determined using a control PCR tube containing 1 mCi of 3 H 2 O. The background diffusion ratio was determined with a cell-free control sample. To calculate the glycolytic rate, the sample diffusion ratio (diffused counts/undiffused counts) minus the background diffusion ratio was divided by the diffusion fraction from the 3 H 2 O control. This number was multiplied by 5500 (nmol of glucose in 0.5 ml of RPMI) to obtain nmol glucose consumed per million cells per hour.
Flow cytometry
For measurements of cell size, cells were incubated with 10 mg/ ml of both propidium iodide and Hoechst 33342 for 30 min at 371C and then analysed on a Becton Dickinson LSR flow cytometer. Mitochondrial membrane potential was evaluated by incubating 500 000 cells with 10 nM TMRE (Molecular Probes) for 30 min at 371C prior to analysis using the LSR cytometer. CCCP (50 mM) and chloroquine (4 mg/ml) were added to duplicate tubes to determine background and confirm that TMRE fluorescence was lost upon dissipation of DCm. Cellular viability was determined by adding 10 mg/ml propidium iodide followed by analysis on the LSR flow cytometer. To evaluate Bax activation, cells were fixed in 0.25% paraformaldehyde for 5 min, washed, and stained with the 6A7 monoclonal antibody (5 mg/ml) or an isotype control followed by an FITC-conjugated secondary antibody in buffer containing 100 mg/ml digitonin, 10% normal rat serum, and Fc Block (BD Pharmingen) in PBS. Cells were then washed with PBS containing 100 mg/ml digitonin and incubated in wash buffer containing 2% FCS, 5 mg/ml propidium iodide, and 100 mg/ml RNAse A for 30 min prior to analysis on a Becton Dickinson FACSCalibur cytometer.
Soft agar assays
p53À/À MEFs were transfected with empty vector, wild-type mTOR, or DTOR and then sorted twice on a MoFlow Cytomation cell sorter to obtain a population of cells expressing high levels of GFP (GFP expression was driven by an IRES sequence following the transgene). Where indicated, cells were transduced with MLV-based retroviral vector encoding E1A and selected in 1 mg/ml puromycin for 2 days prior to plating in soft agar. Live cells (50 000) were plated in 60 mm dishes in DMEM containing 15% FCS, Lglutamine, antibiotics, and 0.38% Noble agar (Difco) layered over a base of 0.6% agar in complete medium. Plates were incubated at 371C in a humidified CO 2 incubator for 5-6 weeks and fed every 3-4 days with 1 ml fresh medium containing 0.38% agar.
